Lupin Launches Lapatinib Tablets

Pharma major Lupin Limited (Lupin) announced today the launch of Lapatinib Tablets, 250 mg, after Lupin's alliance partner Natco Pharma Ltd received final approval for its ANDA from the United States Food and Drug Administration (U.S. FDA).

Lapatinib Tablets, 250 mg, are the generic equivalent of Tykerb® Tablets, 250 mg, of Novartis Pharmaceutical Corporation, and are indicated in combination with:

- Capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2), and who have received prior therapy including an anthracycline, a taxane and trastuzumab

- Letrozole for the treatment of postmenopausal women with hormone-receptor positive metastatic breast cancer that overexpresses the HER2 receptor, for whom hormonal therapy is indicated Lapatinib Tablets (RLD: Tykerb®) had annual sales of approximately USD 61 million in the U.S. (IQVIA MAT June 2020).

Shares of LUPIN LTD. was last trading in BSE at Rs.1006.6 as compared to the previous close of Rs. 998. The total number of shares traded during the day was 124827 in over 4463 trades.

The stock hit an intraday high of Rs. 1025.35 and intraday low of 991. The net turnover during the day was Rs. 126138290.

Source : Equity Bulls

Keywords